Peter Riedell to Immunotherapy, Adoptive
This is a "connection" page, showing publications Peter Riedell has written about Immunotherapy, Adoptive.
Connection Strength
5.546
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
Score: 0.795
-
BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 07 18; 144(3):249-251.
Score: 0.781
-
Advances in CAR T-Cell Therapy for Aggressive B-NHL. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S94-S97.
Score: 0.597
-
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma. 2020 04; 61(4):799-807.
Score: 0.565
-
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
Score: 0.204
-
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
Score: 0.195
-
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531.
Score: 0.195
-
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 07 08; 14(1):108.
Score: 0.195
-
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024 08; 99(8):1624-1627.
Score: 0.193
-
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia. 2024 Jul; 38(7):1564-1569.
Score: 0.193
-
If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary. Transplant Cell Ther. 2024 Jan; 30(1):14-16.
Score: 0.186
-
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
Score: 0.185
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
Score: 0.184
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332.
Score: 0.163
-
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654.
Score: 0.163
-
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
Score: 0.152
-
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
Score: 0.145
-
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb 09; 13(2).
Score: 0.051
-
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025 Jan 11; 405(10473):127-136.
Score: 0.050
-
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 04 25; 143(17):1713-1725.
Score: 0.048
-
Infectious complications of car T-cell therapy: A longitudinal risk model. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14148.
Score: 0.046
-
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
Score: 0.046
-
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
Score: 0.045
-
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13; 389(2):148-157.
Score: 0.045
-
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
Score: 0.042
-
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 04; 28(4):735-742.
Score: 0.042
-
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
Score: 0.039